McKesson Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" McKesson stock.
View analyst ratings for McKesson or view top-rated stocks.

Wall Street analysts have given McKesson a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but McKesson wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

McKesson saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,580,000 shares, an increase of 50.0% from the February 28th total of 1,720,000 shares. Based on an average trading volume of 1,040,000 shares, the days-to-cover ratio is presently 2.5 days. Currently, 1.6% of the company's stock are sold short.
View McKesson's Short Interest.

McKesson is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for McKesson.

McKesson will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

McKesson Co. (NYSE:MCK) posted its quarterly earnings results on Monday, February, 1st. The company reported $4.60 EPS for the quarter, beating analysts' consensus estimates of $4.13 by $0.47. The firm had revenue of $62.60 billion for the quarter, compared to analyst estimates of $61.70 billion. McKesson had a trailing twelve-month return on equity of 45.52% and a net margin of 0.95%. The firm's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.81 EPS.
View McKesson's earnings history.

McKesson's stock was trading at $135.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MCK shares have increased by 42.5% and is now trading at $192.68.
View which stocks have been most impacted by COVID-19.

McKesson announced a quarterly dividend on Thursday, January 28th. Investors of record on Tuesday, March 2nd will be paid a dividend of $0.42 per share on Thursday, April 1st. This represents a $1.68 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, March 1st.
View McKesson's dividend history.

McKesson pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.88%. McKesson has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strock track record of dividend growth. The dividend payout ratio of McKesson is 11.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, McKesson will have a dividend payout ratio of 9.63% next year. This indicates that McKesson will be able to sustain or increase its dividend.
View McKesson's dividend history.

McKesson announced that its board has authorized a stock repurchase program on Tuesday, February 2nd 2021, which permits the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 6.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued.

McKesson updated its FY21 earnings guidance on Tuesday, February, 2nd. The company provided earnings per share (EPS) guidance of $16.95-17.25 for the period, compared to the Thomson Reuters consensus estimate of $16.43.

13 equities research analysts have issued 12-month price objectives for McKesson's shares. Their forecasts range from $165.00 to $231.00. On average, they expect McKesson's stock price to reach $196.00 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price.
View analysts' price targets for McKesson or view top-rated stocks among Wall Street analysts.

220 employees have rated McKesson CEO Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among McKesson's employees.

Some companies that are related to McKesson include AmerisourceBergen (ABC), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO) and Owens & Minor (OMI).
View all of MCK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include The Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and The Home Depot (HD).

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

McKesson's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.03%), Thompson Investment Management Inc. (0.02%), Campbell Capital Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%), Legacy Private Trust Co. (0.01%) and Pensionfund DSM Netherlands (0.01%). Company insiders that own McKesson stock include Brian S Tyler, Brian Scott Tyler, Britt J Vitalone, Lori A Schechter, M Christine Jacobs, Marie L/Ca Knowles, Sundeep G Reddy and Tracy Faber.
View institutional ownership trends for McKesson.

MCK stock was sold by a variety of institutional investors in the last quarter, including Pensionfund Sabic, Legacy Private Trust Co., Hexavest Inc., State of Alaska Department of Revenue, Valeo Financial Advisors LLC, Trust Co. of Toledo NA OH, TrimTabs Asset Management LLC, and Park National Corp OH. Company insiders that have sold McKesson company stock in the last year include Brian S Tyler, Britt J Vitalone, Lori A Schechter, Marie L/Ca Knowles, Sundeep G Reddy, and Tracy Faber.
View insider buying and selling activity for McKesson or view top insider-selling stocks.

MCK stock was bought by a variety of institutional investors in the last quarter, including Everence Capital Management Inc., Pacer Advisors Inc., Campbell Capital Management Inc., Pensionfund DSM Netherlands, Thompson Investment Management Inc., Carroll Financial Associates Inc., Canandaigua National Corp, and First Hawaiian Bank.
View insider buying and selling activity for McKesson or or view top insider-buying stocks.

Shares of MCK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCK stock can currently be purchased for approximately $192.68.

McKesson has a market capitalization of $30.67 billion and generates $231.05 billion in revenue each year. The company earns $900 million in net income (profit) each year or $14.95 on an earnings per share basis.

McKesson employs 80,000 workers across the globe.

The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, ClarusONE Sourcing Services LLP, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, MED3000, McKesson Europe AG, McKesson International Bermuda IP5A Limited, McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLC, McKesson Sourcing Services Inc., McKesson Specialty Care Distribution LLC, McKesson Strategic Services Limited, McKesson UK Finance I Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Northstar Healthcare Holdings Unlimited Company, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.

McKesson was founded in 1833.

The official website for McKesson is www.mckesson.com.

McKesson is headquartered at 6555 STATE HWY 161, IRVING TX, 75039.

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company can be reached via phone at 972-446-4800 or via email at [email protected]